Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Soufflé Therapeutics has raised $200.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Soufflé Therapeutics's investors include Temasek, ARCH Venture Partners, Bessemer Venture Partners, AbbVie, Bayer.
Soufflé Therapeutics is headquartered in Watertown, United States.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
Soufflé Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Soufflé Therapeutics — Funding & Investors." VCBacked, January 1, 2025, https://www.vcbacked.co/company/souffl-therapeutics. Accessed July 21, 2026.
VCBacked. (2025). Soufflé Therapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/souffl-therapeutics
{{cite web |title=Soufflé Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/souffl-therapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated